藥明生物(02269.HK)吐5.5%曾低見86.55元 趁高折讓逾8%配股兼大股東減持
藥明生物(02269.HK)趁高折讓逾8%配股兼大股東減持各籌逾39億元,該股繼昨天升至97.35元創逾16個月高位遇壓後,今早最多回吐6.4%低見86.55元,現造87.45元,回吐5.5%,成交受公司配股上板帶動急增至5,408萬股,涉資46.15億元。
藥明生物以每股85元(較昨天收市價折讓8.1%)向最少六名獨立投資者配售4,650萬股,集資淨額約39.29億元擬用作支持其疫苗和微生物產品開發及繼續進行全球產能擴張。另外,公司大股東Biologics也與配售代理訂立配售協議,擬以同價向獨立第三方配股減持公司4,650萬股,交易完成後,Biologics持股量將由45.68%降至40.44%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.